|
|
|
|
|
|
|
|
|
|
|
14.10.25 - 17:36
|
J&J CFO on Orthopedics Spinoff, Earnings, Drug Pricing (Bloomberg)
|
|
|
Johnson & Johnson CFO Joe Wolk says the company is well positioned for a strong 2026 and discusses plans to spin off its slower-growing orthopedics business and the outlook for drug pricing on “Bloomberg Open Interest.” J&J announced third-quarter sales and earnings that modestly beat expectations, and raised revenue guidance for the full year....
|
|
|
|
|
|
|
|
|
|
|
|
|
14.10.25 - 13:27
|
Johnson & Johnson: Umsatzprognose rauf – Dividenden-Aktie steigt (Der Aktionaer)
|
|
|
Der US-Mischkonzern Johnson & Johnson hat ordentliche Zahlen zum dritten Quartal vorgelegt und wird mit Blick auf das laufende Geschäftsjahr 2025 optimistischer. Zudem will das Unternehmen sein Orthopädie-Geschäft abspalten. Auch die nächste Dividenden-Ausschüttung wurde von Johnson & Johnson festgesetzt....
|
|
|
|
|
|
|
|
|
|
|
14.10.25 - 12:24
|
J&J Raises Sales Guidance, Plans to Split Off Orthopedics Unit (Bloomberg)
|
|
|
Johnson & Johnson said it plans to separate its slower-growing orthopedics business from the rest of the company within 18 to 24 months, giving its innovative drug and device operations more breathing room as the Trump administration pressures pharmaceutical companies to lower prices in the US....
|
|
|
|
|
|
|
|
|
|